Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Whitehead, Mark ^a   Öhlschläger, Peter ^b,c   Almajhdi, Fahad N ^d   Alloza, Leonor ^e   Marzábal, Pablo ^e   Meyers, Ann E ^a   Hitzeroth, Inga I ^a   Rybicki, Edward P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b AACHEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY OF KONSTANZ   (Germany)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cervical cancer; DNA vaccine; E7; HPV 16; Plant produced; Protein body; Zera protein

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; GRANZYME B; PROTEIN E7; UNCLASSIFIED DRUG; ZEIN; ZERA; CANCER VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; RECOMBINANT VACCINE; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EMBRYO; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION SYSTEM; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; INSECT CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CYTOTOXICITY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; ZEIN;

EID: 84901928242     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-367     Document Type: Article

References (34)

1. Eiben GL, da Silva DM, Fausch SC, Le PI, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 2003, 16:111-121. 10.1089/088282403322017866, 12828864.
2. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der MR, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011, 7:1359-1373. 10.4161/hv.7.12.18282, 3338933, 22048172.
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl 3):S3-1-S310.
4. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004, 16:485-491. 10.1097/00001622-200409000-00013, 15314520.
5. Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1996, 8:643-650. 10.1016/S0952-7915(96)80080-X, 8902389.
6. Kennedy RC, Shearer MH, Watts AM, Bright RK. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res 2003, 63:1040-1045.
7. Von Knebel DM, Rittmüller C, Aengeneyndt F, Jansen-Dürr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical phenotype and E6-p52 and E7-PRB interactions. J Virol 1994, 68:2811-2821. 236769, 8151752.
8. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992, 17:312-315. 10.1016/0968-0004(92)90443-D, 1412705.
9. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421. 251060, 2476573.
10. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical Applications of DNA Vaccines: Current Progress. Clin Infect Dis 2011, 53:296-302. 10.1093/cid/cir334, 3202319, 21765081.
11. Ohlschlager P, Pes M, Osen W, Durst M, Schneider A, Gissmann L, Kaufmann AM. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006, 24:2880-2893. 10.1016/j.vaccine.2005.12.061, 16472545.
12. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8:421-439. 10.1517/14712598.8.4.421, 3074340, 18352847.
13. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 2003, 8:s333-s345. 10.2741/1003, 12700045.
14. Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012, 17:469-492. 10.1517/14728214.2012.744393, 3786409, 23163511.
15. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. Plant-based production of biopharmaceuticals. Curr Opin Plant Biol 2004, 7:152-158. 10.1016/j.pbi.2004.01.007, 15003215.
16. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010, 8:620-637. 10.1111/j.1467-7652.2010.00507.x, 20233333.
17. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D. Pivotal trial with plant cell coexpressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118:5767-5773. 10.1182/blood-2011-07-366955, 21900191.
18. Kohl T, Hitzeroth II, Stewart D, Varsani A, Govan VA, Christensen ND, Williamson AL, Rybicki EP. Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol 2006, 13:845-853. 10.1128/CVI.00072-06, 1539125, 16893983.
19. Maclean J, Koekemoer M, Olivier AJ, Stewart D, Hitzeroth II, Rademacher T, Fischer R, Williamson AL, Rybicki EP. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007, 88:1460-1469. 10.1099/vir.0.82718-0, 17412974.
20. Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, Venuti A. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 2007, 25:3018-3021. 10.1016/j.vaccine.2007.01.018, 17280752.
21. Venuti A, Massa S, Mett V, Vedova LD, Paolini F, Franconi R, Yusibov V. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 2009, 27:3395-3397. 10.1016/j.vaccine.2009.01.068, 19200826.
22. Fischer R, Vaquero-Martin C, Sack M, Drossard J, Emans N, Commandeur U. Towards molecular farming in the future: transient protein expression in plants. Biotechnol Appl Biochem 1999, 30(Pt 2):113-116.
23. Torrent M, Geli MI, Ruiz-Avila L, Canals JM, Puigdomenech P, Ludevid D. Role of structural domains for maize gamma-zein retention in Xenopus oocytes. Planta 1994, 192:512-518.
24. Geli MI, Torrent M, Ludevid D. Two Structural Domains Mediate Two Sequential Events in [gamma]-Zein Targeting: Protein Endoplasmic Reticulum Retention and Protein Body Formation. Plant Cell 1994, 6:1911-1922. 160571, 12244234.
25. Torrent M, Llompart B, Lasserre-Ramassamy S, Llop-Tous I, Bastida M, Marzabal P, Westerholm-Pavin A, Saloheimo M, Heifetz PB, Ludevid MD. Eukaryotic protein production in designed storage organelles. BMC Biol 2009, 7:5. 10.1186/1741-7007-7-5, 2637842, 19175916.
26. Torrent M, Llop-Tous I, Ludevid MD. Protein body induction: a new tool to produce and recover recombinant proteins in plants. Methods Mol Biol 2009, 483:193-208. 10.1007/978-1-59745-407-0_11, 19183900.
27. Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998, 16:426-435. 10.1016/S0264-410X(97)00296-X, 9607066.
28. Takeda A, Sugiyama K, Nagano H, Mori M, Kaido M, Mise K, Tsuda S, Okuno T. Identification of a novel RNA silencing suppressor, NSs protein of Tomato spotted wilt virus. FEBS Lett 2002, 532:75-79. 10.1016/S0014-5793(02)03632-3, 12459466.
29. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, Hammerling GJ, Rammensee HG. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997, 27:2391-2399. 10.1002/eji.1830270938, 9341785.
30. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985, 162:1745-1759. 10.1084/jem.162.6.1745, 2187973, 3877776.
31. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, Ter SJ, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23:2242-2249. 10.1002/eji.1830230929, 7690326.
32. Llompart B, Llop-Tous I, Marzabal P, Torrent M, Pallisse R, Bastida M, Ludevid MD, Walas F. Protein production from recombinant protein bodies1. Process Biochem 2010, 45:1816-1820.
33. Voinnet O, Rivas S, Mestre P, Baulcombe D. An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. Plant J 2003, 33:949-956. 10.1046/j.1365-313X.2003.01676.x, 12609035.
34. Skelton D, Satake N, Kohn DB. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther 2001, 8:1813-1815. 10.1038/sj.gt.3301586, 11803402.